Iben Spanggaard
YOU?
Author Swipe
View article: Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results Open
Central nervous system (CNS) tumors often harbor alterations in genes regulating key cellular pathways, including fibroblast growth factor receptor (FGFR) genes. Here, we report the efficacy and safety of treatment with pemigatinib, an ora…
View article: Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors Open
Background Human epidermal growth factor receptor 2 (HER2) aberrations, such as protein overexpression and amplification of the HER2 gene ( ERBB2 ), are well-established in breast and gastroesophageal adenocarcinomas. However, ERBB2 oncoge…
View article: HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, Rigshospitalet
HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, Rigshospitalet Open
When testing for HRD, sensitivity to normal tissue in tumour samples has proven more consequential than previously expected. Based on our findings, HRD status rarely changes over time, and changes in HRD scores may not reflect a genuine bi…
View article: Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients
Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients Open
Background: Cholangiocarcinoma (CCA) is a diverse group of aggressive liver tumors with up to 20% being intrahepatic CCA (iCCA). Up to 15% of patients with iCCA have fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. He…
View article: Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor) Open
Purpose Bromodomain and extra-terminal domain (BET) inhibitors (BETi) have demonstrated epigenetic modulation capabilities, specifically in transcriptional repression of oncogenic pathways. Preclinical assays suggest that BETi potentially …
View article: Mapping MAGE-A4 expression in solid cancers for targeted therapies
Mapping MAGE-A4 expression in solid cancers for targeted therapies Open
Melanoma-associated antigen A4 (MAGE-A4) is a promising target for anticancer therapy. However, limited contemporary data are available on the details of MAGE-A4 protein expression in different cancer types. In this study, the protein expr…
View article: Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors
Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors Open
PURPOSE It is a clinical challenge to select patients for BRAF-targeted therapy because of the lack of predictive biomarkers besides the BRAF V600E mutation. By analyzing the genome, transcriptome, and proteome, this study investigated the…
View article: 628 First-in-human study of CDR404, a novel bivalent and bispecific, antibody-derived, T cell engager in MAGE-A4-positive advanced solid cancers
628 First-in-human study of CDR404, a novel bivalent and bispecific, antibody-derived, T cell engager in MAGE-A4-positive advanced solid cancers Open
View article: Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023
Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023 Open
Background In 2016, genomic profiling was implemented for patients with grade 4 primary brain tumors at Rigshospitalet, Denmark. The aim of this study was to discover actionable alterations and to match these with targeted therapies. Metho…
View article: Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor)
Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor) Open
Purpose Bromodomain and extra-terminal domain (BET) inhibitors (BETi) have demonstrated epigenetic modulation capabilities, specifically in transcriptional repression of oncogenic pathways. Preclinical assays suggest that BETi potentially …
View article: Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies Open
View article: Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial Open
View article: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial Open
View article: Cytokine release syndrome caused by antineoplastic treatment with CAR-T and T-cell engaging therapies
Cytokine release syndrome caused by antineoplastic treatment with CAR-T and T-cell engaging therapies Open
T-cell-based immunotherapy has recently evolved as a treatment option for a number of haematological malignancies and is also being developed in solid tumours. A common side effect of chimeric antigen T-cell therapy (CAR-T) and treatment w…
View article: 87P Enhancing treatment strategies for metastatic high-grade neuroendocrine neoplasms: Insights from extensive genomic profiling through WES and WGS in a phase I clinical setting
87P Enhancing treatment strategies for metastatic high-grade neuroendocrine neoplasms: Insights from extensive genomic profiling through WES and WGS in a phase I clinical setting Open
HG-NEN is a heterogeneous group of rare cancers, including neuroendocrine carcinoma (NEC) and high-grade neuroendocrine tumors (NET G3). HG-NENs are characterized by poor differentiation, rapid growth, limited treatment options and poor pr…
View article: 17P Homologous recombination deficiency status in consecutive tumor biopsies in late-stage cancer patients
17P Homologous recombination deficiency status in consecutive tumor biopsies in late-stage cancer patients Open
Homologous recombination deficiency (HRD) can predict sensitivity to platinum-based chemotherapy and PARP-inhibitors in cancer patients. HRD testing is currently used clinically to decide the optimal course of treatment of high-grade ovari…
View article: Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial Open
NCT01953926 (ClinicalTrials.gov), 2013-002872-42 (EudraCT).
View article: 617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors
617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors Open
Background FAP-CD40 is a second-generation, bispecific, FAP-targeted CD40 agonist antibody, which was developed to overcome systemic toxicities and the narrow therapeutic index of conventional anti-CD40 therapeutics. FAP-CD40 was designed …
View article: 2321TiP TEMPLE: Thiopurine enhanced mutations for PD-1/ligand-1 efficacy: A phase Ib/II clinical trial
2321TiP TEMPLE: Thiopurine enhanced mutations for PD-1/ligand-1 efficacy: A phase Ib/II clinical trial Open
View article: 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study Open
View article: Table of Contents
Table of Contents Open
View article: Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial Open
View article: Supplementary Figure S3. from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Supplementary Figure S3. from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer Open
Comprehensive OncoPrint of nine patients with paired pre- and post-treatment tissue sequencing showing acquired alterations in the post-treatment tumor.
View article: Data from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Data from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer Open
HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in…
View article: Supplementary Figure S3. from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Supplementary Figure S3. from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer Open
Comprehensive OncoPrint of nine patients with paired pre- and post-treatment tissue sequencing showing acquired alterations in the post-treatment tumor.
View article: Supplementary Figure S2 from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Supplementary Figure S2 from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer Open
Overall sequencing CONSORT diagram. Flow diagram of study patients and analyzed biospecimens processed through and selected for central sequencing using MSK-IMPACT and Guardant360. cfDNA, cell-free DNA; FFPE, formalin-fixed paraffin-embedd…
View article: Supplementary Figure S1 from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Supplementary Figure S1 from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer Open
PFS of (A) neratinib plus fulvestrant combination cohort and (B) neratinib monotherapy cohort. CI, confidence interval; PFS, progression-free survival.
View article: Supplementary Data from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Supplementary Data from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer Open
Supplementary data
View article: Supplementary Data from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Supplementary Data from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer Open
Supplementary data
View article: Supplementary Figure S1 from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Supplementary Figure S1 from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer Open
PFS of (A) neratinib plus fulvestrant combination cohort and (B) neratinib monotherapy cohort. CI, confidence interval; PFS, progression-free survival.